- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04640571
Impact of Metformin and Polysorbate 80 on Drug Absorption and Disposition
The study employs two-sub-studies that share a common placebo arm.
The objective of one sub-study is to assess the impact of metformin on pravastatin and chenodeoxycholic acid pharmacokinetics. We hypothesize that metformin represses the bile salt export pump (BSEP) in the liver, which excretes pravastatin and chenodeoxycholic acid from the liver into the bile.
The objective of the other sub-study is to assess the impact of polysorbate 80 on valacyclovir, chenodeoxycholic acid, and enalaprilat pharmacokinetics. We hypothesize that polysorbate 80 inhibits uptake transporters in the intestine, which absorb valacyclovir and chenodeoxycholic acid in the gut via the peptide transporter 1 (PepT1) and apical sodium-bile acid transporter (ASBT), respectively. Enalaprilat is passively absorbed but with low permeability, and thus serves as a passive absorption reference.
Study Overview
Status
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- University of Maryland
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject is healthy, as determined by screening evaluation that is not greater than 60 days before the first study visit.
- Subject is male or female between 18 and 65 years of age, inclusive.
- Subject is an acceptable candidate for venipuncture.
- Subject is willing to stop all non-routine OTC medications, as well as vitamins, dietary supplements, and herbals, for 24 hours prior to study drug administration and during pharmacokinetic study visits.
Exclusion Criteria:
- Subject has a significant medical disease (including cardiovascular, pulmonary, hematologic, endocrine, immunologic, neurologic, renal, gastrointestinal, metabolic, or psychiatric).
- Subject has a clinically significant history or presence of any clinically significant gastrointestinal pathology (e.g. chronic diarrhea, inflammatory bowel diseases), unresolved gastrointestinal symptoms (e.g. diarrhea, vomiting), liver or kidney disease, or other conditions known to interfere with the absorption, distribution, metabolism or excretion of study drugs.
- Subject has a history of liver or gallbladder disease, or history of myopathy
- Subject has a history of angioedema either with or without previous treatment with an angiotensin converting enzyme inhibitor.
- Subject was previously diagnosed with diabetes, or treated with antidiabetic agents
- Subject has a history of alcohol or drug abuse, which in the opinion of the PI or medical physician, could jeopardize the subject's health or would compromise the subject's ability to participate in this trial.
- Subject is pregnant, breast feeding, or trying to become pregnant.
- Female subject of childbearing potential is unwilling or unable to use a medically acceptable method of contraception throughout the entire study period and for one week after the study is completed. Medically acceptable methods of contraception that may be used by the subject and/or her partner are: oral birth control pill, condom with spermicide, diaphragm with spermicide, IUD, vaginal spermicidal suppository, surgical sterilization of patient or their partner(s), abstinence, or hormonal-based patches, ring, injections, and implants.
- Subject routinely uses (i.e. daily or weekly) prescription medication except hormonal birth control medication, routinely uses (i.e. daily or weekly) OTC medication, or routinely uses niacin to treat hypercholesterolemia. OTC medications do not include vitamins, dietary supplements, or herbals.
- Subject routinely uses (i.e. daily or weekly) acid blockers, antacids, anti-diarrhea, stimulants, appetite suppressants, or anti-nausea medication or other drugs that modulate GI function.
- Subject is currently taking metformin, valacyclovir, acyclovir, chenodiol, pravastatin, enalapril, enalaprilat, or medications known to interact with any of these medications.
- Subject has a history or allergy or sensitivity to metformin, valacyclovir, acyclovir, chenodiol, pravastatin, polysorbate 80, enalapril, enalaprilat, or history of any drug hypersensitivity or intolerance which, in the opinion of the PI or medical physician, would compromise the safety of the subject or the study.
- Subject has liver impairment as assessed by alanine aminotransferase (ALT), aspartate aminotransferase (AST), or total bilirubin levels greater than the upper limit of normal (ULN).
- Subject has renal impairment as assessed by creatinine clearance lower than 60mL/min/1.73m2, using the CKDEPI formula.
- Subject is not willing or able to be adherent to study protocol (e.g., study visits).
- Subject has a condition in which in the opinion of the PI or medical physician would increase risk to the subject or interfere with the integrity of the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: placebo, then metformin, then polysorbate 80
Placebo is one twice a day, metformin is 500mg twice a day, and polysorbate 80 is 400mg twice a day
|
single oral dose of pravastatin 80 mg and chenodeoxycholic acid 250 mg
single oral dose of valacyclovir 500 mg, chenodeoxycholic acid 250 mg, and enalaprilat 20 mg
|
Experimental: metformin, then polysorbate 80, then placebo
Placebo is one twice a day, metformin is 500mg twice a day, and polysorbate 80 is 400mg twice a day
|
single oral dose of pravastatin 80 mg and chenodeoxycholic acid 250 mg
single oral dose of valacyclovir 500 mg, chenodeoxycholic acid 250 mg, and enalaprilat 20 mg
|
Experimental: polysorbate 80, then placebo, then metformin
Placebo is one twice a day, metformin is 500mg twice a day, and polysorbate 80 is 400mg twice a day
|
single oral dose of pravastatin 80 mg and chenodeoxycholic acid 250 mg
single oral dose of valacyclovir 500 mg, chenodeoxycholic acid 250 mg, and enalaprilat 20 mg
|
Experimental: polysorbate 80, then metformin, then placebo
Placebo is one twice a day, metformin is 500mg twice a day, and polysorbate 80 is 400mg twice a day
|
single oral dose of pravastatin 80 mg and chenodeoxycholic acid 250 mg
single oral dose of valacyclovir 500 mg, chenodeoxycholic acid 250 mg, and enalaprilat 20 mg
|
Experimental: placebo, then polysorbate 80, then metformin
Placebo is one twice a day, metformin is 500mg twice a day, and polysorbate 80 is 400mg twice a day
|
single oral dose of pravastatin 80 mg and chenodeoxycholic acid 250 mg
single oral dose of valacyclovir 500 mg, chenodeoxycholic acid 250 mg, and enalaprilat 20 mg
|
Experimental: metformin, then placebo, then polysorbate 80
Placebo is one twice a day, metformin is 500mg twice a day, and polysorbate 80 is 400mg twice a day
|
single oral dose of pravastatin 80 mg and chenodeoxycholic acid 250 mg
single oral dose of valacyclovir 500 mg, chenodeoxycholic acid 250 mg, and enalaprilat 20 mg
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area-Under-the-Curve (AUC) of pravastatin
Time Frame: 0-10 hours
|
pravastatin exposure after metformin
|
0-10 hours
|
Peak Plasma Concentration (Cmax) of pravastatin
Time Frame: 0-10 hours
|
pravastatin Cmax after metformin
|
0-10 hours
|
Area-Under-the-Curve (AUC) of chenodeoxycholic acid after metformin
Time Frame: 0-10 hours
|
chenodeoxycholic acid exposure after metformin
|
0-10 hours
|
Peak Plasma Concentration (Cmax) of chenodeoxycholic acid after metformin
Time Frame: 0-10 hours
|
chenodeoxycholic acid Cmax after metformin
|
0-10 hours
|
Area-Under-the-Curve (AUC) of acyclovir
Time Frame: 0-10 hours
|
acyclovir exposure after polysorbate 80
|
0-10 hours
|
Peak Plasma Concentration (Cmax) of acyclovir
Time Frame: 0-10 hours
|
acyclovir Cmax after polysorbate 80
|
0-10 hours
|
Area-Under-the-Curve (AUC) of chenodeoxycholic acid after polysorbate 80
Time Frame: 0-10 hours
|
chenodeoxycholic acid exposure after polysorbate 80
|
0-10 hours
|
Peak Plasma Concentration (Cmax) of chenodeoxycholic acid after polysorbate 80
Time Frame: 0-10 hours
|
chenodeoxycholic acid Cmax after polysorbate 80
|
0-10 hours
|
Area-Under-the-Curve (AUC) of enalapril
Time Frame: 0-10 hours
|
enalapril exposure after polysorbate 80
|
0-10 hours
|
Peak Plasma Concentration (Cmax) of enalapril
Time Frame: 0-10 hours
|
enalapril Cmax after polysorbate 80
|
0-10 hours
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Antimetabolites
- Gastrointestinal Agents
- Protease Inhibitors
- Anticholesteremic Agents
- Hypolipidemic Agents
- Lipid Regulating Agents
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Cathartics
- Angiotensin-Converting Enzyme Inhibitors
- Metformin
- Valacyclovir
- Enalaprilat
- Enalapril
- Chenodeoxycholic Acid
- Pravastatin
Other Study ID Numbers
- HP-00090086
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on pravastatin and chenodeoxycholic acid, after metformin and placebo
-
Leadiant Biosciences, Inc.Not yet recruitingCerebrotendinous Xanthomatoses
-
Humanis Saglık Anonim SirketiCompleted
-
University Hospital, Basel, SwitzerlandCompletedMetabolic Syndrome | Familial Combined Hyperlipidemia | Familial HypertriglyceridemiaSwitzerland
-
Intercept PharmaceuticalsCompletedLiver Cirrhosis, BiliaryUnited States, France, Germany, Spain, United Kingdom, Canada, Austria
-
Intercept PharmaceuticalsCompletedPrimary Biliary CirrhosisUnited States, Spain, United Kingdom, Austria, Netherlands, Australia, Italy, Germany, Poland, Sweden, France, Canada, Belgium
-
Zealand University HospitalCompletedCholelithiasis | Bile Acid MalabsorptionDenmark
-
Imperial College Healthcare NHS TrustCompletedPrimary Bile Acid Malabsorption | Secondary Bile Acid Malabsorption | Chronic DiarrhoeaUnited Kingdom
-
Lars Kristian MunckCompletedBile Acid MalabsorptionDenmark
-
University of AarhusCompletedEffect of Obeticholic Acid on Transport of Bile Acids in PBC Examined by 11C-cholyl-sarcosine PET/CTPrimary Biliary CirrhosisDenmark
-
Intercept PharmaceuticalsCompleted